November 20, 2020
2 min watch
Save
VIDEO: Early treatment with Terlipressin benefits patients with hepatorenal syndrome
Issue: January 2021
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this exclusive video, Andrew Allegretti, MD, MSc, discusses his poster from The Liver Meeting Digital Experience that explored factors associated with response to terlipressin treatment in patients with hepatorenal syndrome.
Allegretti, from Massachusetts General Hospital, and colleagues found that IV albumin use and treating earlier in the phase of illness indicated more successful response, while having a precipitating event for the hepatorenal syndrome was predictive of worse outcomes.
Published by:
Sources/Disclosures
Collapse
Source:
Allegretti A, et al. Abstract 1831. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.
Disclosures:
The authors report no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.